Tech Company Financing Transactions
Casma Therapeutics Funding Round
Casma Therapeutics, based in Cambridge, secured $50 million in investment from The Column Group, Eventide Asset Management and Schroder Adveq.
Transaction Overview
Company Name
Announced On
9/11/2020
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
The Column Group (Lead Investor) (Millie Ray)
Eventide Asset Management (Finny Kuruvilla)
Third Rock Ventures (Cary Pfeffer)
Proceeds Purpose
The proceeds from the financing will allow the company to advance their TRPML1 agonist program into development for muscular dystrophy, as well as continue to develop the Autophagy Degrader Platform (ADP).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 201
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy -- pioneering novel therapeutic strategies to address unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keith Dionne
Chief Operating Officer
Frank Gentile
Chief Scientific Officer
Leon Murphy
Vice President
Daniel Ory
Vice President
Jeffrey Saunders
VP - Finance
Colleen DeSimone
VP - Human Resources
Caren Block
Browse more venture capital transactions:
Prev: 9/11/2020: BinSentry venture capital transaction
Next: 9/11/2020: Korro Bio venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs